Research Progress on Challenges in In Vivo CAR-T Cell Therapy
International Journal of Biology and Life Sciences · 01.11.2026 · 17 (1) · 31-37
DOI: 10.54097/45qbqc61 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biology and Life Sciences, online erschienen am 01.11.2026. Verfasst von Jialing Liu. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The emergence of chimeric antigen receptor (CAR) T-cell therapy heralds a paradigm shift in cancer immunotherapy. Different from in-vitro CAR-T products, in-vivo CAR-T engineering accomplishes in-situ reprogramming of endogenous T cells, making possible long-lasting anti-tumor cytotoxic activity, which is cost-effective in production and has immediate accessibility as an off-the-shelf product. However, challenges like low target specificity, immune suppression in the tumor microenvironment, treatment resistance, and safety concerns do impede its clinical translational application. This review summarizes the main CAR delivery vectors representative preclinical and clinical studies as well as new strategies to overcome current limitations with the purpose of facilitating the clinical development of this emerging therapy.
Zitieren
APA
Liu, J. (2026). Research Progress on Challenges in In Vivo CAR-T Cell Therapy. International Journal of Biology and Life Sciences, 17(1), 31-37. https://doi.org/10.54097/45qbqc61
Vancouver
Liu J. Research Progress on Challenges in In Vivo CAR-T Cell Therapy. International Journal of Biology and Life Sciences. 2026;17(1):31-37. doi:10.54097/45qbqc61
BibTeX
@article{Liu2026,
author = {Liu, Jialing},
title = {Research Progress on Challenges in In Vivo CAR-T Cell Therapy},
journal = {International Journal of Biology and Life Sciences},
year = {2026},
volume = {17},
number = {1},
pages = {31--37},
doi = {10.54097/45qbqc61}
}
EUVIMED